EUROPEAN EXPANSION; MANUFACTURING HIGH QUALITY, LOW COST & LARGE VOLUME CELL & GENE THERAPIES
SPONSORED BY
11:00 – CHAIR INTRODUCTION
Chair: Sanjin Zvonic, Vice President Business Development, Dark Horse
11:05 – FIRESIDE CHAT
Speakers:
Elsa Abranches, Senior Director – Head of Cell Therapy BioProcess Development & Manufacturing, AstraZeneca
Amandine Breton, Director of MSAT & Analytical Sciences, Orchard Therapeutics
Natalie Ward, Associate Director Regulatory Affairs CMC, Adaptimmune
11:30 – CASE STUDY: CURING HEART FAILURE WITH OFF-THE-SHELF ALLOGENEIC HUMAN VENTRICULAR PROGENITOR CELLS
Speakers:
Elsa Abranches, Senior Director – Head of Cell Therapy BioProcess Development & Manufacturing, AstraZeneca
Ryan Hicks, Senior Director – Head of Bioscience Cell Therapy, AstraZeneca
11:45 – CASE STUDY: MANUFACTURING RED BLOOD CELLS
Speaker: Allison Blair, Head of Laboratory, NHSBT
12:00 – CASE STUDY: SETTING UP FOR SUCCESS: PLANNED MANUFACTURING PROCESS CHANGES AS PART OF MANUFACTURING IMPROVEMENTS
Speaker: Natalie Ward, Associate Director Regulatory Affairs CMC, Adaptimmune
12:15 – Q&A WITH SESSION SPEAKERS
Speakers:
Elsa Abranches, AstraZeneca & Ryan Hicks, AstraZeneca
Allison Blair, Head of Laboratory, NHSBT
Natalie Ward, Associate Director Regulatory Affairs CMC, Adaptimmune
Speakers
